Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Abrams

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Future Oncology (London, England)|June 17, 2024
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancerLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JAMA|April 10, 2019
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical TrialKimmie Ng, Halla S Nimeiri, Nadine J McCleary, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Hanrong Feng, Kalindi Parmar, et al.
Cancers|November 25, 2020
Effect of High-Dose vs Standard-Dose Vitamin D<sub>3</sub> Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized TrialJustin C Brown, Michael H Rosenthal, Chao Ma, et al.
The New England Journal of Medicine|January 18, 2023
Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
Cancer Discovery|July 8, 2026
Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancerAndressa Dias Costa, Suryun Kim, Sung Chul Hong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017Al B Benson, Michael I D'Angelica, Daniel E Abbott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2014
Hepatobiliary cancers, version 2.2014Al B Benson, Michael I D'Angelica, Thomas A Abrams, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Future Oncology (London, England)|June 17, 2024
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancerLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JAMA|April 10, 2019
Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical TrialKimmie Ng, Halla S Nimeiri, Nadine J McCleary, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2023
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Hanrong Feng, Kalindi Parmar, et al.
Cancers|November 25, 2020
Effect of High-Dose vs Standard-Dose Vitamin D<sub>3</sub> Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized TrialJustin C Brown, Michael H Rosenthal, Chao Ma, et al.
The New England Journal of Medicine|January 18, 2023
Futibatinib for <i>FGFR2</i>-Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, et al.
Cancer Discovery|July 8, 2026
Impact of vitamin D on the colon cancer immune microenvironment: results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancerAndressa Dias Costa, Suryun Kim, Sung Chul Hong, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017Al B Benson, Michael I D'Angelica, Daniel E Abbott, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2014
Hepatobiliary cancers, version 2.2014Al B Benson, Michael I D'Angelica, Thomas A Abrams, et al.
Pageof 5